462 related articles for article (PubMed ID: 18046415)
1. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.
Zhang X; Pickin KA; Bose R; Jura N; Cole PA; Kuriyan J
Nature; 2007 Nov; 450(7170):741-4. PubMed ID: 18046415
[TBL] [Abstract][Full Text] [Related]
2. Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6.
Park E; Kim N; Ficarro SB; Zhang Y; Lee BI; Cho A; Kim K; Park AKJ; Park WY; Murray B; Meyerson M; Beroukhim R; Marto JA; Cho J; Eck MJ
Nat Struct Mol Biol; 2015 Sep; 22(9):703-711. PubMed ID: 26280531
[TBL] [Abstract][Full Text] [Related]
3. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
[TBL] [Abstract][Full Text] [Related]
4. The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.
Endo H; Okami J; Okuyama H; Nishizawa Y; Imamura F; Inoue M
Oncogene; 2017 May; 36(20):2824-2834. PubMed ID: 27893711
[TBL] [Abstract][Full Text] [Related]
5. Truncation, modification, and optimization of MIG6(segment 2) peptide to target lung cancer-related EGFR.
Yu XD; Yang R; Leng CJ
Comput Biol Chem; 2016 Apr; 61():251-7. PubMed ID: 26967626
[TBL] [Abstract][Full Text] [Related]
6. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.
Jura N; Shan Y; Cao X; Shaw DE; Kuriyan J
Proc Natl Acad Sci U S A; 2009 Dec; 106(51):21608-13. PubMed ID: 20007378
[TBL] [Abstract][Full Text] [Related]
7. Type I γ Phosphatidylinositol Phosphate 5-Kinase i5 Controls the Ubiquitination and Degradation of the Tumor Suppressor Mitogen-inducible Gene 6.
Sun M; Cai J; Anderson RA; Sun Y
J Biol Chem; 2016 Oct; 291(41):21461-21473. PubMed ID: 27557663
[TBL] [Abstract][Full Text] [Related]
8. Coupled folding-upon-binding of human tumor suppressor MIG6 to lung cancer EGFR kinase domain and molecular trimming/stapling of MIG6-derived β-hairpins to target the coupling event.
He Q; Xu S; Ma X; Ling T; Feng W; Lu X; Liu W; Chen Z
Eur Biophys J; 2023 Feb; 52(1-2):17-25. PubMed ID: 36547692
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of Mig6 negatively regulates the ubiquitination and degradation of EGFR mutants in lung adenocarcinoma cell lines.
Boopathy GTK; Lynn JLS; Wee S; Gunaratne J; Hong W
Cell Signal; 2018 Mar; 43():21-31. PubMed ID: 29196224
[TBL] [Abstract][Full Text] [Related]
10. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
Monsey J; Shen W; Schlesinger P; Bose R
J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
[TBL] [Abstract][Full Text] [Related]
11. Exploring the interactions of EGFR with phosphorylated Mig6 by molecular dynamics simulations and MM-PBSA calculations.
Zhang Y; Zheng QC
J Theor Biol; 2018 Jun; 447():118-125. PubMed ID: 29574142
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
13. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
Maity TK; Venugopalan A; Linnoila I; Cultraro CM; Giannakou A; Nemati R; Zhang X; Webster JD; Ritt D; Ghosal S; Hoschuetzky H; Simpson RM; Biswas R; Politi K; Morrison DK; Varmus HE; Guha U
Cancer Discov; 2015 May; 5(5):534-49. PubMed ID: 25735773
[TBL] [Abstract][Full Text] [Related]
14. Understanding the molecular basis of EGFR kinase domain/MIG-6 peptide recognition complex using computational analyses.
Moonrin N; Songtawee N; Rattanabunyong S; Chunsrivirot S; Mokmak W; Tongsima S; Choowongkomon K
BMC Bioinformatics; 2015 Mar; 16():103. PubMed ID: 25885222
[TBL] [Abstract][Full Text] [Related]
15. The juxtamembrane region of the EGF receptor functions as an activation domain.
Red Brewer M; Choi SH; Alvarado D; Moravcevic K; Pozzi A; Lemmon MA; Carpenter G
Mol Cell; 2009 Jun; 34(6):641-51. PubMed ID: 19560417
[TBL] [Abstract][Full Text] [Related]
16. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.
Ferby I; Reschke M; Kudlacek O; Knyazev P; Pantè G; Amann K; Sommergruber W; Kraut N; Ullrich A; Fässler R; Klein R
Nat Med; 2006 May; 12(5):568-73. PubMed ID: 16648858
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Qiu C; Tarrant MK; Choi SH; Sathyamurthy A; Bose R; Banjade S; Pal A; Bornmann WG; Lemmon MA; Cole PA; Leahy DJ
Structure; 2008 Mar; 16(3):460-7. PubMed ID: 18334220
[TBL] [Abstract][Full Text] [Related]
18. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine phosphorylation of mig6 reduces its inhibition of the epidermal growth factor receptor.
Wang Z; Raines LL; Hooy RM; Roberson H; Leahy DJ; Cole PA
ACS Chem Biol; 2013 Nov; 8(11):2372-6. PubMed ID: 24004111
[TBL] [Abstract][Full Text] [Related]
20. The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6.
Menezes SV; Kovacevic Z; Richardson DR
J Biol Chem; 2019 Mar; 294(11):4045-4064. PubMed ID: 30679310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
